Grown Rogue outlines planned acquisition of PharmaCann New York cannabis license assets

• Grown Rogue outlined a planned acquisition of PharmaCann’s New York license and assets via Grown Rogue New York.
• Platform includes four Verilife dispensaries and a 100,000+ sq ft Hamptonburgh cultivation and manufacturing campus.
• Structure gives Grown Rogue 51% common equity; minority partner provides USD 10 million preferred equity for 49%.
• Financing also includes up to a USD 5 million drawable term loan; total committed capital USD 15 million.
• Plan targets about USD 20 million in annual cost reductions; acquisition closing expected in about three months, subject to OCM approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grown Rogue International Inc. published the original content used to generate this news brief on August 21, 2026, and is solely responsible for the information contained therein.